INAB

👉  INAB is TODAY’S #1 ALERT 👈

Hey Folks,

Investors are nervous after Trump telegraphed that his Canada/Mexico tariffs will go into effect imminently.

Personally, I think this is just a negotiating tool and that even if the tariffs get implemented, they won’t last long.

Still, the anxiety has sent the major indexes lower.

However, the official news of a US “Crypto Reserve” is boosting the markets and could be the type of “risk on” news that we needed.

I think it is a little late to chase the moves in digital coins right now, so you’re probably asking, “Where’s a man to find trading opportunities?”

Personally, I’ve had a ton of success lately in identifying small-stock “tactical trade” ideas…

Fifteen of my last 18 such ideas have gone on to double-digit (or better!) gains the day I alerted them, including this doozy from last Tuesday:

Not bad for a single day (especially when the markets got clobbered!)

Today, my #1 “tactical” idea is a small biotech company that’s sitting at a critical support level.

Go to your favorite platform and take close look at the chart for IN8bio, Inc. (INAB).

As you can see, the stock has had some solid runups since October.

We’re talking a 55% gain in three days… a 66% gain in two weeks… even a 152% gain in two days.

And here’s the thing: All of those moves took off from right about the level INAB is sitting at right now.

After seeing the strong price action from the market and IBIO on Friday, I think today could have the potential for another strong liftoff 🚀.

👉  INAB is TODAY’S #1 ALERT 👈

Let’s dive into what makes IN8bio, Inc. a standout in the biotech world. Here are the top 5 things I think investors should know as they get started on their own due diligence:

1. Pioneering Gamma-Delta T Cell Therapies 🧬
   INAB is developing gamma-delta T cell therapies to combat both solid and liquid tumors. These unique cells can tell the difference between healthy and diseased tissue, offering a fresh approach to cancer treatment. They’re not just talking the talk; they’ve brought genetically modified gamma-delta T cells into clinical trials, a first in the industry.

    

2. Robust and Diverse Pipeline 🧪
   Their lineup includes INB-400, currently in a Phase 2 trial targeting glioblastoma (GBM), and INB-100 in Phase 1 for leukemia patients undergoing stem cell transplants. Plus, they’ve got a range of preclinical programs aiming at various solid tumors.

    

3. Recent Positive Clinical Outcomes 🩺
   At the 2024 American Society of Hematology Annual Meeting in December, IN8bio shared encouraging results from their INB-100 trial. All acute myeloid leukemia (AML) patients treated remained in complete remission after a median follow-up of 19.7 months.

    

4. Strategic Financial Moves 💰
   In October 2024, the company secured $12.4 million through a private placement, bolstering their financial position to advance their clinical programs. This move reflects strong investor confidence and provides the necessary funds to push their innovative therapies forward.

    

5. Strategic Expansion in Birmingham 🏢
   The company unveiled a state-of-the-art, 10,000-square-foot research and development facility in Birmingham, Alabama. This move enhances its R&D capabilities and allows it to “benefit from the rich cancer research heritage driven by the University of Alabama at Birmingham (UAB).”

Right now, the three analysts covering INAB give it an average 12-month price target of $3.73 — nearly 1,400% upside from its current price.

Spend time right now doing your own research on the stock, beginning with this detailed investor presentation and the company website.

And of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this page as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: INAB is breaking new ground with their gamma-delta T cell therapies, backed by promising clinical data and strategic financial planning. 

Its stock has had some great moves in the past few months, all bouncing from the support level it’s sitting at right now.

Pay close attention to INAB today to see if we get another runup!

To Your Success,

Jeff Bishop

*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”

Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received fifteen thousand dollars (cash) from Legends Media for advertising IN8bio, Inc a one day marketing program on March 3, 2025. It might seem obvious, but while our client claims not to own any shares in IN8bio, Inc, whoever ultimately paid them most likely owns shares. You should assume they are looking to sell some or all of them at any time after we send out this information, which might negatively affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as the marketing campaign ends, though that is not always the case.

Now, diving right into IN8bio, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies who are paying us and we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1.ties br0ker-deale.r, br0ker, 1nvest.ment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry auth.ority, or any self-regulat0ry organization.

So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.